Mark Eisner

CIK: 0001834161

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

JBIO

Jade Biosciences, Inc.

Director

ZURA

Zura Bio Ltd

Director

VIR

Vir Biotechnology, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

JBIO
Jade Biosciences, Inc.
Jun 25, 2026
Award(A)
Stock Option (Right to Buy)
Direct
47.7K shares-
ZURA
Zura Bio Ltd
Jun 17, 2026
Award(A)
Share Option (Right to Buy)
Direct
51K shares-
VIR
Vir Biotechnology, Inc.
Feb 25, 2026
Sale(S)
Direct
1.9K shares at avg. $9.82$19K
VIR
Vir Biotechnology, Inc.
Feb 24, 2026
Sale(S)
Direct
1.6K shares at avg. $9.53$15K
VIR
Vir Biotechnology, Inc.
Feb 23, 2026
Sale(S)
Direct
2.1K shares at avg. $7.45$16K
VIR
Vir Biotechnology, Inc.
Feb 22, 2026
Award(A)
Direct
55K shares-
ZURA
Zura Bio Ltd
Feb 21, 2026
Award(A)
Share Option (Right to Buy)
Direct
37.8K shares-
VIR
Vir Biotechnology, Inc.
Jul 17, 2025
Sale(S)
Direct
3.6K shares at avg. $5.47$20K
VIR
Vir Biotechnology, Inc.
Jul 15, 2025
Sale(S)
Direct
6.8K shares at avg. $5.47$37K
VIR
Vir Biotechnology, Inc.
Feb 22, 2025
Award(A)
Direct
40K shares-

		Type	Shares	Price		Ownership
Jun 25, 2026	JBIO Jade Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	47,675	-	-	Direct
Jun 17, 2026	ZURA Zura Bio Ltd	Award(A) Share Option (Right to Buy)	51,000	-	-	Direct
Feb 25, 2026	VIR Vir Biotechnology, Inc.	Sale(S)	1,889	$9.82	$18,550	Direct
Feb 24, 2026	VIR Vir Biotechnology, Inc.	Sale(S)	1,616	$9.53	$15,405	Direct
Feb 23, 2026	VIR Vir Biotechnology, Inc.	Sale(S)	2,089	$7.45	$15,569	Direct
Feb 22, 2026	VIR Vir Biotechnology, Inc.	Award(A)	55,000	-	$0	Direct
Feb 21, 2026	ZURA Zura Bio Ltd	Award(A) Share Option (Right to Buy)	37,812	-	-	Direct
Jul 17, 2025	VIR Vir Biotechnology, Inc.	Sale(S)	3,586	$5.47	$19,629	Direct
Jul 15, 2025	VIR Vir Biotechnology, Inc.	Sale(S)	6,796	$5.47	$37,162	Direct
Feb 22, 2025	VIR Vir Biotechnology, Inc.	Award(A)	40,000	-	-	Direct

1-10 of 10 transactions

About Eisner Mark

Eisner Mark (SEC CIK 0001834161) files insider reports with the SEC as Director of Jade Biosciences, Inc. (JBIO), Director of Zura Bio Ltd (ZURA) and EVP and Chief Medical Officer of Vir Biotechnology, Inc. (VIR).

Signal8 holds 9 ownership filings by Eisner Mark (2 Form 3, 7 Form 4), filed between Feb 25, 2025 and Jun 26, 2026. Those filings report 10 transactions, from Feb 22, 2025 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Eisner Mark's filings is in HENDERSON, NV.

Recent filings by Eisner Mark

Jun 25, 2026: Grant or award of JBIO derivative securities (Form 4, code A).
Jun 17, 2026: Grant or award of ZURA derivative securities (Form 4, code A).
Feb 25, 2026: Open-market sale of VIR shares (Form 4, code S).
Feb 24, 2026: Open-market sale of VIR shares (Form 4, code S).
Feb 23, 2026: Open-market sale of VIR shares (Form 4, code S).

Other insiders filing for Jade Biosciences, Inc. (JBIO)

CAIN CHRISTOPHER W., Director
DOBMEIER ERIC, Director
Klein Lawrence Otto, Director
Lavelle Erin, Director
Fairmount Funds Management LLC, Director
Dahms Bradford D., Chief Financial Officer

How to read Form 4 transaction codes